Tekcapital plc License and Development Agreement (9933X)
28 Febbraio 2017 - 8:01AM
UK Regulatory
TIDMTEK
RNS Number : 9933X
Tekcapital plc
28 February 2017
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service ("RIS"), this inside information is now considered to be in
the public domain.
28 February 2017
Tekcapital plc
("Tekcapital" or the "Company")
BELLUSCURA LTD ANNOUNCES OXYGEN CONCENTRATOR LICENSE AND
DEVELOPMENT AGREEMENT
Tekcapital plc (AIM: TEK), an international provider of
technology and intellectual property services, announces that
Belluscura Ltd ("Belluscura") has signed a co-exclusive license and
development agreement with Separation Design Group ("SDG") to
develop a next generation portable oxygen concentrator ("POC"). As
part of the agreement, Belluscura has licensed a portfolio of six
intellectual properties from SDG(1) and has agreed to provide
monthly funding towards the development of a prototype POC
device.
A POC is a device used to deliver concentrated oxygen to a
patient requiring oxygen therapy. POCs are typically prescribed to
people suffering from chronic obstructive pulmonary disease
("COPD"). The World Health Organization has estimated that 64
million people are suffering from moderate to severe COPD around
the world(2) . POCs are generally considered a safer, less
expensive and more convenient treatment for COPD compared to
traditional compressed oxygen cylinders(3) . Ambulatory patients
can benefit from greater personal freedom, with most airlines
permitting their use during flight. The US Federal Aviation
Authority requires all airlines landing in the USA to permit the
use of approved POCs(4) .
SDG is a leading research laboratory in the field of oxygen
concentrators. The Directors believe that the license should allow
Belluscura to access and develop a next generation POC based on
SDG's significant intellectual property portfolio, covering such
features as oxygen enrichment, portability, oxygen conditioning and
convenient and cost-effective maintenance.
Bob Rauker, Belluscura's CEO said: "We are delighted to enter
into this license and development agreement. With the portable
oxygen concentrator market expected to nearly double to $2.2bn by
2021(5) , we believe that this opportunity has the potential to
advance Belluscura's mission of investing in undervalued technology
in order to provide premium medical devices at affordable
prices."
About Belluscura:
Belluscura Limited is a global medical device company founded in
in Oxford, England. Its mission is to make healthcare more
affordable for patients and their providers by providing
proprietary medical devices across a wide variety of treatment and
diagnostic disciplines. Belluscura's products were originally
developed by leading medical device companies or research centres,
and with its unique business model it is able to offer these
devices at affordable prices. To learn more about Belluscura please
visit www.belluscura.com.
Tekcapital owns approximately 65% of the share capital of
Belluscura.
For further information, please contact:
Tekcapital Plc
Clifford M. Gross, Ph.D. info@tekcapital.com
Allenby Capital Limited (Nominated
Adviser & Joint Broker) +44 (0) 20 3328 5656
Jeremy Porter / Alex Brearley
Dowgate Capital Stockbrokers
(Joint Broker) +44 (0) 1293 517744
David Poutney / James Serjeant
Walbrook PR Ltd +44 (0) 20 7933 8780
Paul Cornelius / Helen Cresswell tekcapital@walbrookpr.com
/ Sam Allen
Tekcapital plc - The World's Largest University Network for Open
Innovation
Tekcapital helps clients profit from new, university-developed
intellectual properties. With its proprietary discovery search
engine, linked to 4,500+ universities in 160 countries, coupled
with expert scientific review, Tekcapital provides a turn-key
service to make it easy for clients to find and acquire the IP,
analytics and technology transfer professionals they need to create
a competitive advantage. Tekcapital plc is quoted on the AIM market
of the London Stock Exchange (AIM: symbol TEK) and is headquartered
in Oxford, in the UK. For more information, please visit
www.tekcapital.com
LEI: 213800GOJTOV19FIFZ85
Note 1
Patent Number Priority Title
Date (P)
======================= ============= =========================================
US 9,199,055 B2 P 11/24/2009 Ultra Rapid Cycle Portable Oxygen
Concentrator
----------------------- ------------- -----------------------------------------
US 8,894,751 B2 P 11/24/2009 Ultra Rapid Cycle Portable Oxygen
Concentrator
----------------------- ------------- -----------------------------------------
US Patent Application P 11/24/2009 Ultra Rapid Cycle Portable Oxygen
14/876,133 Concentrator
----------------------- ------------- -----------------------------------------
US 8,888,902 8/15/2012 Portable Oxygen Enrichment Device
and Method of Use
----------------------- ------------- -----------------------------------------
US 8,500,852 4/30/2007 Sorption Method, Device, and
System
----------------------- ------------- -----------------------------------------
US 7,291,271 12/09/2003 Meso-frequency traveling electro-kinetic
continuous adsorption system
----------------------- ------------- -----------------------------------------
Note 2
http://www.who.int/respiratory/copd/en/
Note 3
http://www.inogen.com/resources/oxygen-concentrators/oxygen-tanks-vs-oxygen-concentrators/
Note 4
https://www.faa.gov/about/initiatives/cabin_safety/portable_oxygen/
Note 5
http://www.medgadget.com/2017/02/portable-oxygen-concentrator-market-size-at-744-million-in-2014-is-expected-grow-to-2-2-billion-by-2021.html
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRZMGZZMNRGNZZ
(END) Dow Jones Newswires
February 28, 2017 02:01 ET (07:01 GMT)
Grafico Azioni Tekcapital (LSE:TEK)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Tekcapital (LSE:TEK)
Storico
Da Lug 2023 a Lug 2024
